{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T12:18:22Z","timestamp":1787833102253,"version":"build-2784847793"},"reference-count":56,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Chronic hepatitis D represents the most severe form of viral hepatitis and is associated with higher rates of advanced fibrosis, cirrhosis and hepatocellular carcinoma than hepatitis B monoinfection. It is caused by the hepatitis D virus (HDV), a defective RNA virus that requires co\u2010infection with hepatitis B (HBV) for hepatocyte entry and propagation. Accurate prediction of liver disease sequelae and treatment response using currently available serological biomarkers remains challenging. This article reviews peripheral biomarkers in HDV, including novel biomarkers of HBV activity, exploring their potential clinical utility and areas for future development. Peripheral biomarkers capable of risk stratifying patients with HDV, monitoring or predicting treatment response and elucidating the natural history of infection (including the complex relationship with HBV), would enable individualised care and early identification of those at greater risk of developing advanced liver disease. Establishing the role of these biomarkers in larger, ethnically diverse populations both on existing treatments and in the context of emerging antiviral therapies will be imperative going forward.<\/jats:p>","DOI":"10.1111\/jvh.70225","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:42:25Z","timestamp":1787244145000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Peripheral Biomarkers in Chronic Hepatitis D Infection: A Review"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3534-6349","authenticated-orcid":false,"given":"Zillah","family":"Cargill","sequence":"first","affiliation":[{"name":"Institute of Liver Studies Kings College Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lok","sequence":"additional","affiliation":[{"name":"Institute of Liver Studies Kings College Hospital  London UK"},{"name":"Kings College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Dusheiko","sequence":"additional","affiliation":[{"name":"Institute of Liver Studies Kings College Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Carey","sequence":"additional","affiliation":[{"name":"Institute of Liver Studies Kings College Hospital  London UK"},{"name":"Kings College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.008"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.05.023"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314713"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.05.001"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4"},{"key":"e_1_2_8_7_1","first-page":"10","article-title":"AASLD\/IDSA Practice Guideline on Treatment of Chronic Hepatitis B","volume":"83","author":"Ghany M. G.","year":"2025","journal-title":"Hepatology"},{"key":"e_1_2_8_8_1","article-title":"Performance of Hepatitis Delta Virus (HDV) RNA Testing for the Diagnosis of Active HDV Infection: Systematic Review and Meta\u2010Analysis","volume":"11","author":"Chen S.","year":"2023","journal-title":"Journal of Clinical and Translational Hepatology"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens13010046"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.52.2.396-402.1984"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i1.65"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00049"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2016.05.013"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.68.6.4063-4066.1994"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100842"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1462-5822.2007.01023.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-69304-8"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/ID9.0000000000000128"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31214"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000642"},{"issue":"3","key":"e_1_2_8_21_1","first-page":"1070","article-title":"EASL\u2010AASLD HBV Treatment Endpoints Conference Faculty. Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B\u2010Report From the 2019 EASL\u2010AASLD HBV Treatment Endpoints Conference","volume":"71","author":"Berg T.","year":"2019","journal-title":"Journal of Hepatology"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-010-0648-z"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(91)90404-9"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.4285\/kjt.23.0058"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.10.036"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00430-14"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12895"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002489"},{"key":"e_1_2_8_29_1","doi-asserted-by":"crossref","unstructured":"H.Kamal G.Jargalsaikhan S.Enkhtaivan et\u00a0al. \u201cPrevalence and Risk Factors of Elevated ALT in 3 399 Treatment\u2010Na\u00efve HBV\/HDV Co\u2010Infected Patients: A Comparison With Propensity Score\u2010Matched HBV Mono\u2010Infected Patients. medRxiv \u201d(2025).","DOI":"10.1101\/2025.04.11.25325563"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13734"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1821"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13366"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.05.001"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100686"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-313811"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.05373-11"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i27.2729"},{"key":"e_1_2_8_38_1","first-page":"S53","article-title":"Distinct HBsAg Isoform Patterns Reflect Viral Activity and Disease Stage in Chronic HDV Infection","volume":"58","author":"Grossi I.","year":"2026","journal-title":"Digestive and Liver Disease"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(22)00926-6"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(25)02054-9"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70094"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.01.011"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.10428"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000027941"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.01.035"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.26052"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes11060661"},{"key":"e_1_2_8_48_1","doi-asserted-by":"crossref","unstructured":"H.Wedemeyer S.Aleman A.Blank et\u00a0al. \u201cP158 Final Results of MYR301: A Randomised Phase 3 Study Evaluating the Efficacy and Safety of up to 144\u2009Weeks of Bulevirtide Monotherapy for Chronic Hepatitis Delta and 96\u2009Weeks of Posttreatment Follow\u2010Up \u201d(2025).","DOI":"10.1055\/s-0045-1810987"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14376"},{"key":"e_1_2_8_50_1","unstructured":"I.Carey M.Anderson C.Moigboi et\u00a0al. \u201cLarge HBsAg Protein is High in HDV RNA Positive Patients \u201d(2022)."},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13804"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-330644"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab597"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.11.051"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25792"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000099"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-63497-w"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.70225","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.70225","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.70225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:25:52Z","timestamp":1787829952000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.70225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/jvh.70225"],"URL":"https:\/\/doi.org\/10.1111\/jvh.70225","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"2026-06-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70225"}}